# CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2010

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2010-11-03
- Accepted by EDGAR: Nov 3, 2010, 17:01 ET
- Period: 2010-09-30
- Accession: 0001193125-10-246290
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000119312510246290/d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000119312510246290/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2010-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2010-07-01 to 2010-09-30 | $23.88bn | us-gaap:Revenues |
| Revenue | 9 months, 2010-01-01 to 2010-09-30 | $71.64bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2010-07-01 to 2010-09-30 | $18.85bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2010-01-01 to 2010-09-30 | $56.85bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2010-07-01 to 2010-09-30 | $5.02bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2010-01-01 to 2010-09-30 | $14.79bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2010-07-01 to 2010-09-30 | $1.48bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2010-01-01 to 2010-09-30 | $4.39bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2010-07-01 to 2010-09-30 | $138.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2010-01-01 to 2010-09-30 | $402.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2010-07-01 to 2010-09-30 | $528.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2010-01-01 to 2010-09-30 | $1.58bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2010-07-01 to 2010-09-30 | $809.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2010-01-01 to 2010-09-30 | $2.40bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2010-07-01 to 2010-09-30 | $0.59 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2010-01-01 to 2010-09-30 | $1.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2010-07-01 to 2010-09-30 | $0.59 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2010-01-01 to 2010-09-30 | $1.75 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2010-07-01 to 2010-09-30 | 1,368,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2010-01-01 to 2010-09-30 | 1,378,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2010-01-01 to 2010-09-30 | $3.00bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2010-01-01 to 2010-09-30 | $1.38bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2010-01-01 to 2010-09-30 | $360.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2010-01-01 to 2010-09-30 | $1.50bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2010-09-30 | $979.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2010-09-30 | $17.34bn | us-gaap:AssetsCurrent |
| Total assets | at 2010-09-30 | $61.71bn | us-gaap:Assets |
| Current liabilities | at 2010-09-30 | $11.67bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2010-09-30 | $8.65bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2010-09-30 | $1.10bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2010-09-30 | $1.38bn | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2010-09-30 | $36.64bn | us-gaap:StockholdersEquity |

## Market risk

As filed, 293 characters.

As of September 30, 2010, the Company had no derivative financial instruments or derivative commodity instruments in place and believes that its exposure to market risk associated with other financial instruments, principally interest rate risk inherent in its debt portfolio, is not material.

## Controls and procedures

As filed, 8,172 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of September 30, 2010, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that occurred in the three months ended September 30, 2010 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our Annual Report of Form 10-K for the year ended December 31, 2009 and Part II, Item 1 of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010 and June 30, 2010. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

### I. Legal Proceedings

1\. Beginning in November 2008, the Company received and responded to several subpoenas from the Drug Enforcement Administration (“DEA”), Los Angeles Field Division, requesting sales data and other information regarding the Company’s distribution of products containing pseudoephedrine (“PSE”) at certain retail pharmacies and from one California distribution center. In September 2009, the United States Attorney’s Office for the Central District of California (“USAO”) and the DEA commenced discussions with the Company regarding whether, in late 2007 and 2008, the Company distributed PSE in violation of the Controlled Substances Act. In addition, the DEA issued an order to show cause against certain retail pharmacies and the Company’s La Habra, California distribution center which could have resulted in administrative action against the Company’s DEA registrations for these facilities. On October 13, 2010, the Company entered into a comprehensive resolution of this matter, resulting in the payment of $75 million in civil penalties for violations of the Controlled Substances Act and $2.6 million in criminal forfeiture relating to the sales of products containing PSE. The resolution included the entry of a non-prosecution agreement and civil settlement agreement with the USAO, the U.S. Attorney’s Office for the District of Nevada and the DOJ, as well as a memorandum of agreement with the DEA that dismisses the above-referenced orders to show cause and contains certain ongoing compliance requirements for the Company.

2\. In December 2007, the Company received a document subpoena from the Office of Inspector General, United States Department of Health and Human Services (“OIG”), requesting information relating to the processing of Medicaid and other government agency claims on another adjudication platform of Caremark. The Company has initiated discussions with the OIG and with the U.S. Department of Justice (“DOJ”) concerning our government claims processing activities. In October 2009 and October 2010, the Company received civil investigative demands from the Office of the Attorney General of the State of Texas requesting, respectively, information produced under the OIG subpoena referenced above and information related to the processing of Medicaid claims. These civil investigative demands state that the Office of the Attorney General of the State of Texas is investigating allegations currently pending under seal relating to two of Caremark’s adjudication platforms. The Company is cooperating with the requests for information contained in the OIG subpoena and in these civil investigative demands. The Company cannot predict with certainty the timing or outcome of any review of such information.

3\. Since March 2009, the Company has been named in a series of eight putative collective or class action lawsuits filed in federal courts in Connecticut, Florida, Illinois, Massachusetts, New York and Rhode Island, purportedly on behalf of current and former assistant store managers working in the Company’s stores at various locations outside California. The lawsuits allege that the Company failed to pay overtime to assistant store managers under the Fair Labor Standards Act (“FLSA”) and under certain state statutes. The lawsuits also seek other relief, including liquidated damages, attorneys’ fees, costs and injunctive relief arising out of the state and federal claims for overtime pay. In May 2010, a federal court in Florida conditionally certified a collective action under the FLSA involving current and former assistant store managers at the Company’s retail stores in Florida, and authorized notices to be issued to potential opt-in plaintiffs. In August 2010, a federal court in New York conditionally certified a collective action under the FLSA involving current and former assistant store managers at all of the Company’s retail stores, excluding those in California and Florida, and authorized notices to be issued to potential opt-in plaintiffs. At this time, the Company is not able to predict the outcome of these lawsuits, or any possible monetary exposure associated with the lawsuits. The Company believes, however, that the lawsuits are without merit and that the cases should not be certified as class or collective actions, and is vigorously defending these claims.

### Part II Item 2

### II. Environmental Matters

Item 103 of SEC Regulation S-K requires disclosure of certain environmental legal proceedings if management reasonably believes that the proceedings involve potential monetary sanctions of $100,000 or more. On October 22, 2010, the Company entered into a Consent Order with the State of Connecticut to address alleged noncompliance with state wastewater discharge regulations and related notices of violation issued with respect to certain of its stores in Connecticut. As part of the negotiated Order, the Company has agreed to make certain operational changes with respect to its wastewater discharges from stores within the state, fund a supplemental environmental project in the amount of $45,000 and pay a $223,900 civil penalty to resolve the allegations in the Order. The Company is continuing to evaluate its rights under a service and support agreement it has with a third-party vendor to be indemnified for, among other things, the payments the Company is required to make pursuant to the Consent Order. Negotiations remain ongoing with the State of Connecticut regarding additional environmental compliance matters unrelated to wastewater discharge. The Company cannot predict the ultimate outcome of these negotiations; however, management does not believe that the outcome will have a material adverse effect on the Company.

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended September 30, 2010, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2010 Repurchase Program.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| July 1, 2010 through July 31, 2010 | — | $— | — | $2,000,000,000 |
| August 1, 2010 through August 31, 2010 | — | $— | — | $2,000,000,000 |
| September 1, 2010 through September 30, 2010 | — | $— | — | $2,000,000,000 |

38

### Part II Item 6

### Exhibits

Filed Nov 3, 2010.
Source: SEC EDGAR, the filing index for accession 0001193125-10-246290. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
